CreativeOne Wealth LLC Has $4.52 Million Position in Pfizer Inc. $PFE

Key Points

• CreativeOne Wealth LLC increased its Pfizer Inc. stake by 31.7%, acquiring a total of 178,513 shares valued at approximately $4.52 million.
• Recent analyst ratings show mixed opinions on Pfizer, with a consensus target price of $28.12 and two analysts giving it a "Strong Buy" rating.
• Pfizer reported earnings of $0.78 per share for the last quarter, surpassing expectations, with revenue of $14.65 billion, indicating a year-over-year growth of 10.3%.

CreativeOne Wealth LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 31.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 178,513 shares of the biopharmaceutical company's stock after purchasing an additional 42,949 shares during the period. CreativeOne Wealth LLC's holdings in Pfizer were worth $4,523,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Bessemer Group Inc. increased its stake in Pfizer by 11.1% during the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after acquiring an additional 13,228 shares during the period. Capital Advisors Inc. OK boosted its holdings in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after acquiring an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp acquired a new stake in shares of Pfizer during the 1st quarter valued at $8,283,000. Alta Advisers Ltd raised its position in Pfizer by 69.6% during the 1st quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock worth $809,000 after purchasing an additional 13,100 shares during the last quarter. Finally, WCM Investment Management LLC raised its position in Pfizer by 8.7% during the 1st quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock worth $3,176,000 after purchasing an additional 10,051 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PFE. Morgan Stanley lifted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. HSBC cut their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. UBS Group boosted their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Leerink Partners lowered their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. Finally, Jefferies Financial Group lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Stock Up 0.6%

NYSE PFE opened at $25.08 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The business's 50-day moving average is $24.76 and its 200 day moving average is $24.40. The stock has a market capitalization of $142.57 billion, a PE ratio of 13.34, a PEG ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's revenue was up 10.3% on a year-over-year basis. During the same period last year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer's payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.